Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer by stopping blood flow to the tumor.

Key facts

Study ID

NCT00003850

Run by

National Cancer Institute (NCI)

People needed

47

Starts

1999-04-01

Last updated by the study team

2013-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.